Colchicine Dosing for Gout
Acute Gout Flare Treatment
For acute gout flares, administer colchicine 1.2 mg (two tablets) at the first sign of symptoms, followed by 0.6 mg (one tablet) one hour later, for a total maximum dose of 1.8 mg over one hour. 1, 2
- This low-dose regimen is FDA-approved and demonstrates efficacy comparable to previously used high-dose regimens while maintaining a safety profile indistinguishable from placebo. 1, 3
- Early administration at the very first indication of a flare is critical for optimal pain reduction—delay significantly reduces effectiveness. 1
- The American College of Rheumatology recommends a "medication-in-pocket" approach, where patients who can recognize early symptoms keep colchicine readily available for immediate self-administration. 1
- Treatment must be initiated within 36 hours of symptom onset to achieve meaningful benefit. 4
Critical Pitfall to Avoid
- Never use the outdated high-dose regimen (1.2 mg followed by 0.6 mg hourly for six hours, totaling 4.8 mg), as it offers no additional therapeutic benefit but markedly increases severe gastrointestinal adverse effects including diarrhea (77% incidence) and vomiting (17% incidence). 1, 3
- Higher doses beyond 1.8 mg total have not been found to be more effective. 2
Gout Flare Prophylaxis
For prophylaxis of gout flares, prescribe colchicine 0.6 mg once daily or 0.6 mg twice daily (maximum 1.2 mg/day) in adults with normal renal and hepatic function. 1, 2
- Once-daily dosing (0.6 mg) is preferred over twice-daily dosing, as recent evidence shows no superiority of twice-daily regimens in preventing flares, while once-daily dosing reduces intolerability and costs. 5
- Prophylaxis should be continued for a minimum of six months when initiating any urate-lowering therapy (allopurinol, febuxostat, or pegloticase). 1, 2
- Initiation of urate-lowering agents without colchicine prophylaxis significantly increases the risk of flares due to crystal mobilization from changing serum uric acid levels. 1, 2
Evidence on Prophylaxis Duration
- While FDA labeling and guidelines recommend at least 6 months of prophylaxis 1, 2, recent Korean population data suggests that at least 3 months of prophylaxis may be sufficient to maximize persistence with urate-lowering therapy. 6
- However, colchicine prophylaxis is necessary even with "start-low go-slow" allopurinol titration strategies—placebo was not non-inferior to colchicine in preventing flares during the first 6 months. 7
- Both colchicine (0.5 mg daily) and low-dose steroids (7.5 mg prednisone equivalent daily) reduce flare frequency and severity, but colchicine is superior to steroids in flare prophylaxis. 8
When to Avoid Prophylaxis
- Do not initiate long-term urate-lowering therapy (and therefore prophylaxis) after a single gout attack or in patients experiencing fewer than two attacks per year, as prophylactic benefit is limited in these scenarios. 1
Dosing During Concurrent Prophylaxis and Acute Flare
If an acute gout flare occurs while a patient is already taking prophylactic colchicine, administer the acute flare dose (1.2 mg followed by 0.6 mg one hour later), then wait 12 hours before resuming the prophylactic dose. 2
Drug Interactions and Contraindications
Colchicine is absolutely contraindicated in patients with renal or hepatic impairment who are concurrently receiving potent CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole, ritonavir) or P-glycoprotein inhibitors due to high risk of fatal toxicity. 1, 2
Dose Adjustments for Drug Interactions
When strong CYP3A4 or P-glycoprotein inhibitors cannot be avoided in patients with normal renal/hepatic function:
- For prophylaxis: Reduce from 0.6 mg twice daily to 0.3 mg once daily, or from 0.6 mg once daily to 0.3 mg every other day. 2
- For acute flares: Reduce from the standard 1.8 mg total dose to 0.6 mg × 1 dose followed by 0.3 mg one hour later; do not repeat for at least 3 days. 2
Renal Impairment Dosing
- Mild renal impairment (eGFR 60-89 mL/min/1.73 m²): No dose adjustment needed; standard 0.6 mg daily maintains therapeutic levels. 9
- Moderate renal impairment (eGFR 30-59 mL/min/1.73 m²): Reduce prophylactic dose to 0.48-0.5 mg daily to avoid supratherapeutic levels (standard 0.6 mg results in 10% excursion above maximum tolerated level). 9
- Severe renal impairment (eGFR 15-29 mL/min/1.73 m²): Reduce prophylactic dose to 0.3 mg daily (standard 0.6 mg results in 36% excursion above maximum tolerated level). 9
- Splitting conventional 0.6 mg tablets or using every-other-day dosing in moderate renal impairment results in subtherapeutic levels for 20-70% of the dosing interval; precise dosing with oral solution (if available) is preferred. 9
Alternative First-Line Agents for Acute Flares
While colchicine is an acceptable first-line option, the American College of Physicians strongly recommends oral corticosteroids (e.g., prednisolone 35 mg daily for 5 days) as the preferred first-line pharmacologic option for acute gout due to a more favorable safety profile and comparable efficacy to NSAIDs and colchicine. 4
- Corticosteroids are particularly preferred in patients with chronic kidney disease, congestive heart failure, cirrhosis, prior gastrointestinal bleeding, or those receiving anticoagulation—all populations in whom NSAIDs and colchicine carry higher risks. 4
- Any NSAID at full anti-inflammatory dose may be used as an alternative when corticosteroids are contraindicated, with no evidence that indomethacin is superior to other NSAIDs. 4